Brief: Kezar Life Sciences Announces Interim Results From Mission Phase 2 Trial In Patients With Lupus Nephritis

Kezar Life Sciences

15/11/2021 21:25

Nov 15 (Reuters) - Kezar Life Sciences Inc  KZR.O :
    * KEZAR LIFE SCIENCES ANNOUNCES INTERIM RESULTS FROM MISSION
PHASE
2 TRIAL IN PATIENTS WITH LUPUS NEPHRITIS
    * KEZAR LIFE SCIENCES INC - KZR-616 MAINTAINED A FAVORABLE
SAFETY
AND TOLERABILITY PROFILE OVER SIX-MONTH TREATMENT PERIOD
    * KEZAR LIFE SCIENCES INC - TOP-LINE DATA FROM PHASE 2
MISSION
TRIAL IN PATIENTS WITH LUPUS NEPHRITIS ARE EXPECTED IN Q2 OF
2022

Source text for Eikon:  ID:nBw9gGnxNa 
Further company coverage:  KZR.O 

 ((Reuters.Briefs@thomsonreuters.com;))